{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwP6S6ZoKDA","lastupdate":"2022-10-31T00:00:00.000Z","update_date":"2022-10-31T00:00:00.000Z","lastModified":"Feb 25, 2025","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"emendo-biotherapeutics","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by AnGes on Dec, 2020","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$wfseuVlNQWCc4rIKtK6HlNwfEsL0yNLEu4hRdnJ3jFyxBqQd5EXmeV","name":"Emendo Biotherapeutics","oneliner":"DNA Correction and Genome-editing Platforms","registrar":"515372027","website":"https://www.emendobio.com/","careerspage":"","founded_month":5,"founded_year":2015,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/10443839","instagram":""},"social":["https://www.linkedin.com/company/10443839"],"flattenedsociallinks":"https://www.linkedin.com/company/10443839","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":42,"patent":1,"raised":73000000,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Emendo Bio","EmendoBio"],"about":"Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene therapy.  \n\nEmendo genome-editing technology can repair and eliminate genetic mutations in living cells that cause serious diseases or disorders. Emendo's gene-editing solutions are recombination based, highly specific, and have zero off-target effect.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97286837368","country":null,"address":{"israeli":[{"id":"2c90108d-23df-4bfd-9b8a-ca1559efed6e","city":" ","type":null,"address":"Ilan Ramon Street 2, Ness Ziona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"9dedd265-def6-4064-964a-1eea755c2cf8","city":"New York","address":"400 W 61st St, New York, NY, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":null,"news":[{"id":"h1Tm7UymuGc9OkBFMSEAUv0m441NbBKCbeH56RHmArgJorXpNJy27f","date":"Dec 20, 2023","link":"https://www.calcalistech.com/ctechnews/article/hkju5txpt","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Layoffs, Acquisition","company":"AnGes","layoffs":"110 employees","summary":"Japanese pharmaceutical company AnGes is laying off 110 employees at Israeli gene editing technology firm EmendoBio, which it acquired for $250 million in 2020. The future of EmendoBios technology is uncertain. AnGes, which is listed on the Tokyo stock exchange, has seen a significant drop in its share price in recent years. Despite this, it had previously stated it would continue to support EmendoBios operations in Israel and the US. EmendoBio, founded in 2015, uses protein engineering for precision gene editing to treat certain genetic disorders and diseases.","partners":"Not mentioned","customers":"Not mentioned","investors":["OrbiMed life sciences fund","Private investors","AnGes"],"confidence":8,"key_topics":["Layoffs","Acquisition","Gene Editing Technology","Share Collapse","Investment"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-negative","investment_amount":"$73 million","structured_issues":["Layoffs","Acquisition"],"acquisition_amount":"$250 million","structuredIssuesShow":"#Layoffs  #Acquisition","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"O4RRJiEKDafUyXUNnKy32NmD5Tvot8AiEXlL3j3h5VCUySIbo2PTi0","news_summary":"AnGes laying off 110 EmendoBio employees three years after $250 million acquisition | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3DuG2v2M05jnfNaIEWRrW8crC8nvbKZzth164QrX7r0wX2zmHqWc63","date":"Dec 20, 2023","link":"https://www.themarker.com/technation/2023-12-20/ty-article-live/.premium/00000181-ce84-d7b6-a9df-cebff18b0000","source":"www.themarker.com","visible":1,"analysis":{"tags":"Closure, Layoffs","company":"EmendoBio","layoffs":"110","summary":"Japanese pharma company AnGes is closing down EmendoBio, a genetic editing company it acquired three years ago. EmendoBio, based in Rehovot, currently employs about 110 people in Israel and a few in New York in the fields of molecular biology and bioinformatics. The employees were notified of the closure at the beginning of the week and are now undergoing hearings. The Israeli management of the company refused to comment on the news.","partners":"N/A","customers":"N/A","investors":"AnGes","confidence":9,"key_topics":["Company Closure","Employee Layoffs"],"date_of_event":"December 20, 2023","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Layoffs"],"acquisition_amount":"N/A","structuredIssuesShow":"#Layoffs","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"0ZQzaU70po99bh2jik601w4rvqXORQdQSqPbnPjIpbxeMqoRCCVxqc","news_summary":"אמזון מפטרת גם בישראל; מיקרוסופט בסבב קיצוצים נרחב","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"XUBI9blHei0PtavcY1MOjVnm55Gch4PmhOx8tD4o7KrejbixlNYfg9","date":"May 17, 2022","link":"https://www.businesswire.com/news/home/20220517006030/en/Emendo-Biotherapeutics%E2%80%99-next-generation-CRISPR-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-ELANE-related-Severe-Congenital-Neutropenia-as-presented-at-ASGCT-Annual-Meeting","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"vF49753Pk5Bz00naTMR5D8LgtOi9Dia2g2acZRGPJovaH3DlLZbafL","news_summary":"Emendo Biotherapeutics' next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"xeiLgsts5O6AxRyb729RskzMjtSEEPBHwE2GosqUz2vrQle7iYhxI8","date":"Dec 22, 2021","link":"https://www.businesswire.com/news/home/20211222005552/en/Emendo-Biotherapeutics-and-Seattle-Children%E2%80%99s-Research-Institute-Announce-Collaboration-to-Develop-CRISPR-based-Therapeutic-Strategy-for-Severe-Congenital-Neutropenia","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"qXEbHCFbF3rYxMa6UiaE8E1fW7AcTgb2h9CndIMOlHsSN2sazAsrNb","news_summary":"Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe Congenital Neutropenia","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"SXeVfHjM5N5cyC7F9On0VvwULQhKanqrgshBE4N9ebOkY56Bqu0UJc","date":"Dec 8, 2021","link":"https://www.businesswire.com/news/home/20211208006008/en/Emendo-Biotherapeutics-to-Present-New-Data-at-63rd-ASH-Annual-Meeting-Exhibition","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"ZeqJseTEHY5SI3BZncrStwPi0lwACd92KTPXEhZ055aQkZ9h8QCQLw","news_summary":"Emendo Biotherapeutics to Present New Data at 63rd ASH Annual Meeting & Exhibition","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"k4mtUzNX0eHOd25jYbedP9efFZ9HWQjqspdTBHbeZf3QeE00vCD4re","date":"Jan 8, 2021","link":"https://www.vivebiotech.com/en/about-us/news/vivebiotech-collaborates-with-emendo-biotherapeutics/","source":"www.vivebiotech.com","visible":1,"analysis":{"tags":"Partnership, Manufacturing","company":"VIVEbiotech","layoffs":"N/A","summary":"VIVEbiotech has announced a collaboration with Emendo Biotherapeutics for the development and manufacturing of lentiviral vectors in clinical quality. EmendoBio, a company that develops gene therapies for diseases of genetic origin, has chosen VIVEbiotech as its partner for this project. The manufacturing will take place at VIVEbiotechs new facilities in San Sebastián, which will allow for increased innovation and manufacturing capabilities of specialist lentiviral vectors.","partners":"Emendo Biotherapeutics","customers":"Emendo Biotherapeutics","investors":"N/A","confidence":9,"key_topics":["Collaboration","Gene Therapy"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"chPyUwn7YAjkwylpYcStzIlMVhhzrdiurRVv7QabcPvdBcDtknbgJX","news_summary":"VIVEbiotech collaborates with Emendo Biotherapeutics - VIVEBiotech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bb41f5c8-8cca-4928-95a3-3878380177f6","date":"Dec 15, 2020","link":"https://www.businesswire.com/news/home/20201215005542/en/EmendoBio-Gene-Editing-Company-Acquired-by-AnGes-Inc<span id=\"ms-outlook-android-cursor\">!~OMSelectionMarkerEnd~","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"0BJTiUCce7bjylEiZgJdYv65B7QL80ttJyfa9guGu1Wf3yDccsvtir","news_summary":"EmendoBio Gene Editing Company Acquired by AnGes, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"80a296de-0d30-4c46-9cf3-e5c758a9efdc","date":"Jan 15, 2020","link":"https://en.globes.co.il/en/article-gene-editing-co-emendo-biotherapeutics-raises-61m-1001314945","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Gene Editing","company":"Emendo Biotherapeutics","layoffs":"Not mentioned","summary":"Gene editing company Emendo Biotherapeutics has raised $61 million in a Series B investment round led by Japans AnGes, Inc. The company, which has its R&D office in Ness Ziona, uses synthetic biology to develop next-generation gene editing solutions for untreatable diseases. Emendos OMNI technology allows for precision gene editing while maintaining high efficiencies. The funding will be used to accelerate the OMNI gene editing platform towards a broad clinical pipeline for addressing untreatable diseases.","partners":["AnGes, Inc.","OrbiMed Advisors","OrbiMed Israel Partners","Takeda Ventures"],"customers":"Not mentioned","investors":["AnGes, Inc.","OrbiMed Advisors","OrbiMed Israel Partners","Takeda Ventures"],"confidence":9,"key_topics":["Gene Editing","Investment","Synthetic Biology","Untreatable Diseases","OMNI Technology"],"date_of_event":"January 15, 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$61 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6VR0vVfrWHR5Vidd8Z1Hwi7Sz1sOyllrgecAHE3N5C6Rqyu4371VfH","news_summary":"Gene editing co Emendo Biotherapeutics raises $61m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":8,"techcommunityinvolvement":null,"mediagallery":[{"id":"b8389fdc-381a-4a2b-98fa-58f046bd5c2d","timestamp":"2017-06-06 10:38:26.000000","resources_type":1,"resources_title":"","resources_file_name":"$xVq60pVVDV3p7XbTAo6jeIpS8uS0oZb2Tfg3ndG9MkRBReLJY6Sz9B","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$xVq60pVVDV3p7XbTAo6jeIpS8uS0oZb2Tfg3ndG9MkRBReLJY6Sz9B","url":"https://storage.googleapis.com/clean-finder-353810/$xVq60pVVDV3p7XbTAo6jeIpS8uS0oZb2Tfg3ndG9MkRBReLJY6Sz9B"}],"tags":["genome-editing","gene-editing","biopharmaceutical","genomics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":[],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$61M","totalrounds":2,"fundingstage":"Acquired","totalfunding":"$73M","publicinvestors":2,"lastpublicfunding":61000000,"totalpublicrounds":2,"totalpublicfunding":73000000},"team":[{"name":"David Baram, Ph.D.","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwL7dqoIKDA","bounced":false,"claimed":0,"founder":0,"urlname":"david-baram-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAvvaqnwkM","position":"President & CEO","last_name":"Baram, Ph.D.","claimtoken":"JIMPsteXccG4B1IG88KwZD2vY1fgfcm57tNZ6oNercYZtfUcj7C5d1","first_name":"David","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-baram-aa6b2a3/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-10-31 22:15:03.000000","initials":"DB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Shilo Ben-Zeev","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwL6hoJQJDA","bounced":false,"claimed":0,"founder":1,"urlname":"shilo-ben-zeev-1","visible":0,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAvvKKjAkM","position":"Co-founder","last_name":"Ben-Zeev","claimtoken":"12a395c627e555c93de7c2d74f83d299168bda0a5aaccb38eb3a33586e6e65cd","first_name":"Shilo","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/shilobz/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2020-10-21 09:17:52.000000","initials":"SB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"},{"name":"Lior   Izhar","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Iat3JEIDA","bounced":false,"claimed":0,"founder":1,"urlname":"lior-izhar-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg5pX-wQgM","position":"Co-founder & CTO","last_name":"Izhar","claimtoken":"7bIuRKYjSnAbBfGdRYj2XzjIQHmrYUi5fBpiq5gakoEUM0DrgCa7jw","first_name":"Lior  ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/lior-izhar-bab68a84/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-10-31 22:15:40.000000","initials":"LI","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liat  Shamay  Zadikov","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LWh-b8IDA","bounced":false,"claimed":0,"founder":0,"urlname":"liat-shamay-zadikov","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg9Z326ggM","position":"Head of HR","last_name":"Zadikov","claimtoken":"N3fIPI5rKnIIyt4gYiAMm4auQ1AtixzIXmZHUneLvExn3FmyMsDMS0","first_name":"Liat  Shamay ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/liat-zadikov-946a21/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-10-31 22:16:53.000000","initials":"LZ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2020-01-20T00:00:00.000Z","crunchbaseid":"emendo-biotherapeutics","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2016-11-09T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Jenny Sotnik-Talisman","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODTsrubCgw","date":"Dec 2020","amount":"$250M","source":"https://www.calcalistech.com/ctechnews/article/hkju5txpt, https://www.businesswire.com/news/home/20201215005542/en/EmendoBio-Gene-Editing-Company-Acquired-by-AnGes-Inc<span id=\"ms-outlook-android-cursor\">!~OMSelectionMarkerEnd~","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"AnGes","acquiredcompany_mna_id":"Zq1OKaFmOeTTjFHwGxKjMFh6IQRET8NkMOU6psWE73veJA6li21oAn","acquiredcompany_mna_type":"Multinational","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/mnc_page/anges","acquiredcompany_mna_logokey":"$K8dAcIkEGgPnSukt5NhqhuhSMbxWwdtUCjXEFdMEhHqOf7OWVysELa.jpeg","acquiredcompany_mna_urlname":"/mnc_page/anges","acquiredcompany_mna_homepage":"https://www.anges.co.jp/en/","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$K8dAcIkEGgPnSukt5NhqhuhSMbxWwdtUCjXEFdMEhHqOf7OWVysELa.jpeg","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":250000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODGhObkCgw","date":"Jan 2020","amount":"$61M","source":"https://en.globes.co.il/en/article-gene-editing-co-emendo-biotherapeutics-raises-61m-1001314945","eventtype":"FundingRoundEvent","investment":[{"name":"OrbiMed","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7556d5d7-7370-4cea-9ee5-c73162a1dda5","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","leadcaption":"","followupcaption":""},{"name":"Takeda Ventures","type":"Investor","amount":0,"hidden":false,"country":"Japan","fullurl":"/investor_page/takeda-ventures","logokey":"$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","tagline":null,"urlname":"/investor_page/takeda-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NWZ7KkIDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"e3c8d559-040c-45dc-9d93-cd6f420ece7c","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":61000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCouOOXCgw","date":"Oct 2016","amount":"$12M","source":"https://pitchbook.com/profiles/company/230000-59#funding","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":12000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"5/2015","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Emendo Biotherapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$wfseuVlNQWCc4rIKtK6HlNwfEsL0yNLEu4hRdnJ3jFyxBqQd5EXmeV","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$wfseuVlNQWCc4rIKtK6HlNwfEsL0yNLEu4hRdnJ3jFyxBqQd5EXmeV","seoabout":"Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene t...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"},{"title":"Pharmaceuticals","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Biotechnology","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODTsrubCgw","date":"Dec 2020","amount":"$250M","source":"https://www.calcalistech.com/ctechnews/article/hkju5txpt, https://www.businesswire.com/news/home/20201215005542/en/EmendoBio-Gene-Editing-Company-Acquired-by-AnGes-Inc<span id=\"ms-outlook-android-cursor\">!~OMSelectionMarkerEnd~","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"AnGes","acquiredcompany_mna_id":"Zq1OKaFmOeTTjFHwGxKjMFh6IQRET8NkMOU6psWE73veJA6li21oAn","acquiredcompany_mna_type":"Multinational","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/mnc_page/anges","acquiredcompany_mna_logokey":"$K8dAcIkEGgPnSukt5NhqhuhSMbxWwdtUCjXEFdMEhHqOf7OWVysELa.jpeg","acquiredcompany_mna_urlname":"/mnc_page/anges","acquiredcompany_mna_homepage":"https://www.anges.co.jp/en/","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$K8dAcIkEGgPnSukt5NhqhuhSMbxWwdtUCjXEFdMEhHqOf7OWVysELa.jpeg","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":250000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODGhObkCgw","date":"Jan 2020","amount":"$61M","source":"https://en.globes.co.il/en/article-gene-editing-co-emendo-biotherapeutics-raises-61m-1001314945","eventtype":"FundingRoundEvent","investment":[{"name":"OrbiMed","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7556d5d7-7370-4cea-9ee5-c73162a1dda5","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","leadcaption":"","followupcaption":""},{"name":"Takeda Ventures","type":"Investor","amount":0,"hidden":false,"country":"Japan","fullurl":"/investor_page/takeda-ventures","logokey":"$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","tagline":null,"urlname":"/investor_page/takeda-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NWZ7KkIDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"e3c8d559-040c-45dc-9d93-cd6f420ece7c","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":61000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCouOOXCgw","date":"Oct 2016","amount":"$12M","source":"https://pitchbook.com/profiles/company/230000-59#funding","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":12000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}